)
Visual21 Nov 2025
Data center suppliers
Vaxcyte (PCVX) investor relations material
Vaxcyte Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary19 Nov, 2025
Program updates and clinical progress
Advancing a 31-Valent Pneumococcal Conjugate Vaccine, with phase III pivotal study in adults set to begin December 2024.
Phase II data in adults showed superior coverage and immune response compared to current 20-Valent standard.
Infant program underway, with learnings from VAX-24 applied to VAX-31 for broader coverage and higher immunogenicity.
PD3 and PD4 data for infants expected by first half of 2027, with disclosure strategy to be announced early next year.
Manufacturing capacity expanded with Lonza and Thermo Fisher to support anticipated demand for both adult and infant launches.
Market landscape and growth outlook
Pneumococcal vaccine market currently $8–10 billion, expected to grow to $12–15 billion in 5–10 years.
Adult segment projected to expand rapidly, potentially reaching parity with infant segment due to new universal recommendations.
U.S. lowered adult vaccination age from 65 to 50, making 63 million more Americans eligible.
Market shift from one-dose to prime-boost regimen anticipated, pending broader valent vaccine approvals.
Competitive landscape includes large pharma advancing 25- and 30-plus valent programs, but trailing in clinical progress.
Regulatory and strategic considerations
Positive and stable interactions with FDA, no unusual requirements for efficacy or safety studies.
Ongoing engagement with policymakers and agencies to advocate for vaccine importance.
Phase III study design and comparator selection to be disclosed soon, with no expected impact on trial size or timeline.
Financial position strong, with $2.7 billion in cash sufficient to fund operations and milestones into mid-2028.
How to leverage prime-boost in adult PCV market?
Infant PD3/PD4 data disclosure strategy
Confirm manufacturing readiness for infant launch
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Vaxcyte earnings date
Evercore ISI 8th Annual HealthCONx Conference2 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Vaxcyte Inc. is a clinical-stage biotechnology company focused on the development of novel protein vaccines aimed at preventing or treating bacterial infectious diseases. Its leading vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease. In addition to VAX-24, Vaxcyte is working on several other vaccine candidates, including VAX-31, to address emerging strains and antibiotic resistance; VAX-A1, targeting Group A Streptococcus; VAX-PG, aimed at a keystone pathogen responsible for periodontitis; and VAX-GI, to prevent Shigella. The company is headquartered in San Carlos, California and its shares are listed on the NASDAQ stock exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage